Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer

Lei Jin 1,*
Xuemei Ma 2,*
Nan Zhang 3
Qian Zhang 4
Xueming Chen 1
Zhongtao Zhang 2
Qian Zhang 4
Xueming Chen 1
Zhongtao Zhang 2
Guoqian Ding 2
Hongzi Yu 1

1Department of Vascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Department of Radiology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 4Department of Radiology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China

*These authors contributed equally to this work

Purpose: This study aimed to explore the value of miR-181a-2-3p in cisplatin (DDP) treatment effectiveness prediction, and to reveal the function underlying the reversal of DDP resistance in patients with gastric cancer (GC).

Methods: miRNA expression dataset of three DDP-resistant GC cell lines and their DDP-sensitive parental cell lines obtained from GEO DataSets and GenBank, and functional miRNAs were annotated by bioinformatics analyses. Serum specimens and tumor samples were collected from 91 GC patients for understanding of the interrelation between chemotherapy response and miRNA expression. RT-qPCR validated these miRNAs at the transcriptional level in both gastric cancer cells and 91 gastric cancer patients. The correlation between the miRNAs expression and clinical parameters of the patients were analyzed. Receiver operating characteristics (ROC) analysis has been utilized to assess the diagnostic performance. The MTT and colony formation assays were performed to assess cell proliferation. Flow cytometry was conducted to detect cell apoptosis. DDP-resistant GC cells and their DDP-sensitive parental cells were transfected with miRNA mimic or inhibitor vector to overexpress or downregulate miRNA expression.

Results: miR-181a-2-3p as a unique miRNA was found in the common differentially expressed-miRNAs (DE-miRNAs) after miRNA screening and validation from three DDP-resistant and DDP-sensitive gastric cancer cell lines. Clinical data analysis displayed that miR-181a-2-3p expression was apparently increased in larger tumor size (≥5 cm), higher T stage (T4), and chemotherapy resistance. miR-181a-2-3p (AUC=0.926, SE=0.028, 95% CI: 0.872–0.980, p<0.0001) differentiated chemosensitive GC patients from chemoresistant GC patients. miR-181a-2-3p presented a higher level in gastric cancer, and could serve as a valid biomarker to predict the overall survival of GC patients. Upregulation of miR-181a-2-3p rendered the apoptosis-inducing and anti-proliferative effects of DDP, while downregulating it decreased these effects.

Conclusion: miR-181a-2-3p can function as a therapeutic target and a tumor biomarker. Targeting oncogenic miR-181a-2-3p inhibits growth and suppresses cisplatin resistance of gastric cancer.

Keywords: biomarker, miR-181a-2-3p, cisplatin resistance, gastric cancer, bioinformatic analysis

Introduction
Gastric cancer, a non-negligible malignant cancer, is prevalent worldwide, making it the fourth most commonly diagnosed cancer and the second leading cause of cancer death.1 There were about 691,000 cases of gastric adenocarcinoma...
worldwide in 2012.2 An estimated 720,000 patients died from gastric cancer in that year.3 Due to the high prevalence of metastasis, drug-resistance, and recurrence, the current long-term survival rate of GC patients is poor.4 Cisplatin (DDP) is considered as a first-line agent for advanced GC patients. DDP exerts an antitumor effect through activating several apoptosis pathways.5 In most GC patients, DDP resistance is inevitable, thus causing treatment failure. Hence, seeking novel targets and biomarkers and elucidating the underlying molecular mechanisms are urgently needed for improved outcomes.

miRNAs are an existing class of small noncoding RNAs.6 In many tumors, their dysregulation may give rise to DDP resistance, which is yet to be fully understood.7,8 In human serum specimens of multiple neoplasms, miRNAs might serve as biomarkers for treatment prognosis and sensitivity.9–11 The potential mechanisms of antitumor drug resistance may be relevant to miRNA-mediated proliferation and apoptosis.12 Some reports have been published on the relationship between the miRNA utilization and the initiation, progression, diagnosis, appropriate treatment and prognosis of the GC.13–15 Nonetheless, specific miRNAs that act as a prognostic biomarker for GC chemotherapy remain to be uncovered.

In the current work, microRNA profiles were analyzed in GC cells to discover the unique miRNAs. The correlation between miRNA expression and clinical prognosis was evaluated using clinical specimens from GC patients after DDP therapy. We tried to uncover unique biomarkers for chemotherapy response and their role underlying the reversal of DDP resistance in GC patients.

**Materials and Methods**

**Cell Lines, Cultures and Reagents**

Human gastric cancer cell lines (AGS, NCI-N87, MGC-803, SGC-7901, BGC-823 and MKN-45) and human gastric epithelial cell line (GES-1) were acquired from the Chinese Academy of Medical Sciences (Beijing, China). DDP-resistant GC cell lines (SGC-7901/DDP, SGC-7901, BGC-823/DDP and BGC-823) were produced and established from parental cell lines (SGC-7901, MGC-803 and BGC-823). Specific culture conditions and reagents for experiments are previously described.15–17

**Plasmids and Transfection**

Expression plasmids for the miR-181a-2-3p mimics control, miR-181a-2-3p mimics, miR-181a-2-3p inhibitor and miR-181a-2-3p inhibitor control were obtained from Fulengene. Specific transfection procedure and reagents for experiments are almost the same as previously described, except for the concentration of RT-qPCR (2x10^5/well), MTT assays (3x10^3/well), and colony formation assays (2x10^2/well).14

**Patient Enrollment and Ethics Statement**

Serum specimens and tumor samples of 91 GC patients were collected. Inclusion and exclusion criteria for enrolled patients and evaluation criteria for chemotherapy response effect are performed as described before.14,16,18 Informed consent of all patients was obtained. This study was approved by the Ethics Committee of Beijing Friendship Hospital (Approval Number: 2018-P2-045-01), Capital Medical University. The study was conducted in accordance with the Declaration of Helsinki.

**miRNA Microarray and Data Analysis**


| log2 (Fold Change) | > 1 with P-value< 0.05 was accepted as statistically significant to calculate differentially expressed-miRNAs (DE-miRNAs) between the cisplatin resistant GC cell line and its sensitive parental cell line by the edgeR algorithm.

**Bioinformatics Analysis**

The common DE-miRNAs were picked out by taking the intersection. Venn diagram of the common DE-miRNAs was calculated and drawn via the Bioinformatics & Evolutionary Genomics web tool (http://bioinformatics.psb.ugent.be/webtools/Venn). Starbase database (http://starbase.sysu.edu.cn/index.php) was utilized to verify the expression levels of DE-miRNAs in gastric cancer and its normal tissues, and to verify the correlation between DE-miRNAs and survival time in gastric cancer. OncomiR database (http://www.oncomir.org/), OncoLnc database (http://www.oncolnc.org/), and Kaplan–Meier Plotter database (http://kmplot.com) were adopted to verify the association between DE-miRNAs and overall survival in gastric cancer.20–23
RNA Extraction and RT-qPCR
Caenorhabditis elegans cel-39-3p miRNA was selected as an external calibration for RNA Extraction and RT-qPCR for serum samples. The primers sequence for miRNA detection is listed in Table 1. Specific procedure of RNA Extraction and RT-qPCR are the same as previously described.14,15

MTT Assay
Before this assay, cells were cultured under normal conditions or as indicated for the DDP-treated conditions. Cells were counted at a concentration of 3×10^3/well into 96-well plate. After adhere, cells were treated with DDP (200 μL/well) at the indicated concentrations for 48 h. Specific MTT procedure and reagents for experiments are the same as previously described.14

Colony Formation Assay
Specific colony formation procedure and reagents for experiments are almost the same as previously described, except for the concentration of colony formation assays (2×10^3/well).14

Flow Cytometric Analysis of Apoptosis
Specific flow cytometry procedure and reagents for experiments are the same as previously described.14

Statistical Analysis
Specific statistical analysis is almost the same as previously described.14,15 For the in vitro experiments, statistical differences were analyzed using the unpaired Student’s t-test and one-way ANOVA followed by Tukey’s multiple comparisons test. Associations between the clinical parameters of the patients and their miRNA expression were analyzed using the Mann–Whitney test. The expression level distribution of miR-181a-2-3p in different groups is presented as the median and interquartile range [median (Q1 and Q3)]. All data were expressed as mean±SD. Each experiment was repeated independently at least three times. Quantitative data were analyzed and graphically represented using SPSS 26.0, MedCalc, and GraphPad Prism 8. Differences were considered to be significant at ****P<0.0001, **P<0.01, *P<0.05, and #P<0.01.

Results
miRNA Screening and Validation from DDP-Sensitive and DDP-Resistant Gastric Cancer Cell Lines
The differentially expressed-miRNAs (DE-miRNAs) in DDP-resistant GC cells and their parental DDP-sensitive cells were determined by miRNA microarray analysis. Scanning and counting the DE-miRNAs, there were 68 miRNAs between SGC-7901 and SGC-7901/DDP, 94 miRNAs between BGC-823 and BGC-823/DDP, and 35 miRNAs between MGC-803 and MGC-803/DDP (Supplementary Table 1). The common DE-miRNAs were picked out by taking the intersection of these three paired cell lines, and was shown using Venn diagram (Figure 1A). miR-181a-2-3p as a unique miRNA was found in the intersection, and was chosen for further study.

Furthermore, RT-qPCR analysis was performed to validate miR-181a-2-3p expression level. The results revealed that miR-181a-2-3p expression was significantly upregulated ~22.2-fold in SGC-7901/DDP cells (compared with SGC-7901 cells), ~4.9-fold in BGC-823/DDP cells (compared with BGC-823 cells), and ~17.1-fold in MGC-803/DDP cells (compared with MGC-803 cells), which proved the correlation between DDP resistance and miR-181a-2-3p expression level (Figure 1B). The above results indicate that miR-181a-2-3p may influence the DDP resistance of GC cells.

Expression Levels and Functions of miR-181a-2-3p in GC Serum and Tumor Samples
Table 2 summarizes the clinicopathological characteristics of 91 GC patients who received palliative treatment or neoadjuvant chemotherapy. RT-qPCR analysis was utilized to test miR-181a-2-3p levels of GC serum specimens and tumor samples in different clinical parameters. Using the median ratio as the cutoff for miR-181a-2-3p expression (Fold Change=0) in GC serum specimens and tumor samples, patients were divided into two groups: miR-181a-2-3p^low and miR-181a-2-3p^high.

The results show that miR-181a-2-3p expression was markedly elevated in larger tumor size (≥5 cm; P<0.0010, Figure 2A; P_tumor=0.0002, Figure 2D), higher T stage (T4; P_tumor=0.0006, Figure 2B; P_tumor=0.0016, Figure 2E), and chemotherapy resistance (SD+PD; P<0.0001, Figure 2C; P_tumor<0.0001, Figure 2F) both in GC serum specimens and tumor samples. What’s more, miR-181a-2-3p expression was obviously increased in abnormal CEA level (P=0.0200, Supplementary Figure 1A) and abnormal CA19-9 level (P=0.0015, Supplementary Figure 1B) in GC serum specimens. Additionally, miR-181a-2-3p expression was
obviously increased in worse Grades stage (G3+G4, \( P = 0.0184 \), Supplementary Figure 1C), present lymph node metastasis (\( P = 0.0280 \), Supplementary Figure 1D), and higher TNM stage (IV, \( P < 0.0001 \), Supplementary Figure 1E) in GC tumor samples. These results suggest that in GC patients, miR-181a-2-3p may function as a biomarker for DDP response and be related to tumor growth. However, miR-181a-2-3p expression was not related with gender, age, CA724 level, CA125 level, or M stage both in GC serum specimens and tumor samples (Table 2).

miR-181a-2-3p could distinguish the GC chemotherapy response-sensitive group (CR+PR) from the GC chemotherapy response-resistant group (SD+PD). Receiver operating characteristic (ROC) curve was utilized to predict the diagnostic efficacy of miR-181a-2-3p. The results for the area under the curves (AUC), standard error (SE), 95% confidence intervals (CI), and \( P \)-values of miR-181a-2-3p in GC serum specimens and tumor samples were as follows: miR-181a-2-3pserum (AUC: 0.821, SE: 0.045, 95% CI: 0.733–0.909, \( p < 0.0001 \), Figure 2G) and miR-181a-2-3ptumor (AUC: 0.843, SE: 0.041, 95% CI: 0.762–0.924, \( p < 0.0001 \), Figure 2G), respectively.

miR-181a-2-3p both in GC serum specimens and tumor samples offered potential AUC values to differentiate CR+PR groups from SD+PD groups. Comparing to the individual sample type (serum specimens or tumor samples), the combined sample type gained a significantly improved performance, determined by: miR-181a-2-3pserum + tumor (AUC: 0.926, SE: 0.028, 95% CI: 0.872–0.980, \( p < 0.0001 \), Figure 2H). The risk score factors (RSF) of the logistic model were calculated as 0.591 \( \times \) miR-181a-2-3pserum + 0.729 \( \times \) miR-181a-2-3ptumor + 0.231.

A comparison between miR-181a-2-3pserum and miR-181a-2-3ptumor was not significantly different (\( P = 0.708 \), Figure 2G). The compared areas of miR-181a-2-3pserum + tumor and miR-181a-2-3pserum were significantly different (\( P = 0.011 \), Figure 2H). The compared areas of

<table>
<thead>
<tr>
<th>miRNA Symbol</th>
<th>Article Number</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-181a-2-3p</td>
<td>HmiRQP0233</td>
<td>CCAGTCACTGACCTGACTGTACCA</td>
</tr>
<tr>
<td>let-7g-5p</td>
<td>HmiRQP0001</td>
<td>TGAGGAGTAGATTGTACAGTTAA</td>
</tr>
<tr>
<td>U6</td>
<td></td>
<td>Not available</td>
</tr>
</tbody>
</table>

**Table 1** Primers of RT-qPCR

Abbreviation: U6, U6 small nuclear RNA.
Table 2 The Correlation Between miR-181a-2-3p Expression and Clinical Parameters in GC Patients (n=91)

<table>
<thead>
<tr>
<th>Clinical Parameters</th>
<th>Cases (n)</th>
<th>Serum Specimens</th>
<th>Tumor Samples</th>
<th>P value</th>
<th>Expression Level</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Expression Level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>58</td>
<td>0.1127 (-1.3708, 3.0470)</td>
<td>0.2123</td>
<td>0.4635 (-2.1063, 2.0662)</td>
<td>0.3625</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>33</td>
<td>-0.1065 (-2.4170, 2.5489)</td>
<td>0.6320</td>
<td>-0.8298 (-1.3388, 1.3412)</td>
<td>0.2960</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>31</td>
<td>-0.1631 (-1.4325, 2.3352)</td>
<td>0.0010***</td>
<td>-1.2899 (-2.7163, -0.6463)</td>
<td>0.0002***</td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>60</td>
<td>0.6245 (-1.5613, 2.8365)</td>
<td>0.6821</td>
<td>1.3134 (-1.3087, 2.1362)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size(cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 5</td>
<td>28</td>
<td>-1.5476 (-3.1598, 2.0861)</td>
<td>0.5186</td>
<td>-1.2738 (-2.9631, -0.5638)</td>
<td>0.0184*</td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>63</td>
<td>1.146 (-1.0845, 2.9981)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grades stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good (G1+G2)</td>
<td>22</td>
<td>0.9554 (-0.4081, 2.3648)</td>
<td>0.2000*</td>
<td>-0.2090 (-1.9263, 1.3615)</td>
<td>0.2320</td>
<td></td>
</tr>
<tr>
<td>Bad (G3+G4)</td>
<td>69</td>
<td>-0.1606 (-1.6248, 2.8651)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>50</td>
<td>-0.3892 (-2.2321, 2.3573)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal</td>
<td>41</td>
<td>1.1146 (-1.1296, 3.4678)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA724 level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>35</td>
<td>-0.1065 (-1.6033, 2.3352)</td>
<td>0.1832</td>
<td>0.2323 (-2.0533, 1.3618)</td>
<td>0.2877</td>
<td></td>
</tr>
<tr>
<td>Abnormal</td>
<td>56</td>
<td>0.5118 (-1.4099, 3.0246)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA125 level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>54</td>
<td>0.5234 (-1.3708, 2.7677)</td>
<td>0.2751</td>
<td>0.0667 (-2.3832, 1.8362)</td>
<td>0.4459</td>
<td></td>
</tr>
<tr>
<td>Abnormal</td>
<td>37</td>
<td>-0.6566 (-2.1921, 2.5514)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA19-9 level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>30</td>
<td>-0.5406 (-3.0416, 1.3282)</td>
<td>0.0015**</td>
<td>-0.3302 (-2.4436, 1.8872)</td>
<td>0.6427</td>
<td></td>
</tr>
<tr>
<td>Abnormal</td>
<td>61</td>
<td>1.1099 (-1.3211, 3.2041)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>32</td>
<td>-1.4325 (-2.9116, 1.3625)</td>
<td>0.0006***</td>
<td>-1.3109 (-2.4332, 0.6987)</td>
<td>0.0016**</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>59</td>
<td>1.3456 (-0.9364, 3.0516)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>58</td>
<td>-0.2908 (-1.5127, 2.5864)</td>
<td>0.5031</td>
<td>-0.7438 (-2.3481, 1.3633)</td>
<td>0.0280*</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>33</td>
<td>1.2761 (-1.5545, 2.6645)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>48</td>
<td>-0.1952 (-1.5205, 2.6085)</td>
<td>0.9024</td>
<td>1.2352 (-1.4763, 1.8737)</td>
<td>0.1329</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>43</td>
<td>0.8212 (-1.5476, 2.7016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>30</td>
<td>1.1846 (-0.5992, 2.6458)</td>
<td>0.3231</td>
<td>-1.4804 (-3.0338, -1.0463)</td>
<td>&lt;0.0001****</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>61</td>
<td>-0.4210 (-1.6248, 2.5761)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy response</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitive (CR+PR)</td>
<td>41</td>
<td>-1.3873 (-2.4342, -0.2274)</td>
<td>&lt;0.0001****</td>
<td>-1.5298 (-3.0886, -0.8311)</td>
<td>&lt;0.0001****</td>
<td></td>
</tr>
<tr>
<td>Resistant (SD+PD)</td>
<td>50</td>
<td>2.5173 (0.3744, 3.5036)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: The formula for expression level is log2(Fold Change). Expression levels are shown with median and quartile spacing. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
miR-181a-2-3p<sub>serum</sub> and miR-181a-2-3p<sub>tumor</sub> were significantly different \((P=0.006\), Figure 2I). The results suggest that higher levels of miR-181a-2-3p<sub>serum</sub> is a better biomarker for chemoresistance in GC patients.

**Bioinformatics Analysis and Validation of miR-181a-2-3p in Gastric Cancer**

To ascertain the expression of miR-181a-2-3p in gastric cancer, Starbase database and RT-qPCR were used to analyse and validate. Starbase database showed miR-181a-2-3p got a higher expression in 372 gastric cancer samples, compared with 32 gastric normal samples (Figure 3A). RT-qPCR confirmed that miR-181a-2-3p was at a relatively high level in most human GC cell lines (AGS, MGC-803, BGC-823 and SGC-7901), compared with GES-1 (Figure 3B). Additionally, compared to adjacent non tumor tissue, miR-181a-2-3p presented a higher level in gastric cancer tissue (Figure 3C and D).

A large cohort analysis was performed via Kaplan–Meier survival data based on OncoLnc database, Kaplan–Meier Plotter database, OncomiR database, and Starbase database in order to find out the function of miR-181a-2-3p as a potential prognostic factor. The results showed that GC patients with higher miR-181a-2-3p levels had obviously shorter 10-year overall survival (OS) times than those with lower levels in Kaplan–Meier Plotter.
OncoLnc database (P = 0.00506, Figure 3F), OncomiR database (P = 0.003906, Figure 3G), and Starbase database (P = 0.0045, Figure 3H), which suggested that miR-181a-2-3p could function as a promising biomarker for overall survival of GC patients.

Upregulation of miR-181a-2-3p Renders GC Cells Resistance to DDP

The aforementioned results suggested that miR-181a-2-3p expression was significantly upregulated ~22.2-fold in SGC-7901/DDP cells (compared with SGC-7901 cells) and ~17.1-fold in MGC-803/DDP cells (compared with MGC-803 cells), which was higher than that in BGC-823/DDP cells (~4.9-fold, compared with BGC-823 cells) (Figure 1B). So, we chose these two pairs cell lines (MGC-803 with MGC-803/DDP, and SGC-7901 with SGC-7901/DDP) for further study. To explore the function of miR-181a-2-3p in DDP resistance, miR-181a-2-3p was subsequently overexpressed in MGC-803 and SGC-7901 cells, and downregulated in MGC-803/DDP and SGC-7901/DDP cells via transient transfection.

RT-qPCR proved that compared with that in mimics control cells, miR-181a-2-3p level was significantly increased in MGC-803 and SGC-7901 cells transfected with miR-181a-2-3p mimics (Figure 4A). In order to verify the correlation between miR-181a-2-3p overexpression and DDP resistance, MGC-803 and SGC-7901 cells were transfected with either miR-181a-2-3p mimics or mimic control. Cell activity was tested after 48 h (Figure 4B). MGC-803 and SGC-7901 cells transfected with the miR-181a-2-3p mimics showed marked increase in survival rates and higher DDP IC50 values, comparing to the mimics control (Figure 4C). Furthermore, higher levels of miR-181a-2-3p were correlated with increased cell proliferation after culture with 0.2 μg/mL DDP in SGC-7901 cells or 0.8 μg/mL DDP in MGC-803 cells (Figure 4D). Comparing to the mimics control cells, the relative colony forming efficiency in both MGC-803 and SGC-7901 cells transfected with the miR-181a-2-3p mimics got a significant increase (Figure 4E). Besides, compared with the mimics control cells, MGC-803 and SGC-7901 cells transfected with miR-181a-2-3p mimics exhibited decreased rates of apoptosis after culture with 0.2 μg/mL DDP and 0.8 μg/mL DDP, respectively (Figure 4F and G). Therefore, miR-181a-2-3p overexpression increased DDP resistance, caused by decrease in apoptosis and cytotoxicity. The above results substantiate that miR-181a-2-3p overexpression renders DDP resistance in gastric cancer cells.
Downregulation of miR-181a-2-3p Sensitizes GC Cells to DDP

RT-qPCR proved that miR-181a-2-3p level was markedly decreased in MGC-803/DDP and SGC-7901/DDP cells transfected with miR-181a-2-3p inhibitor, comparing to inhibitor control cells (Figure 5A). To demonstrate the association between DDP resistance and miR-181a-2-3p downregulation, MGC-803/DDP and SGC-7901/DDP cells were transfected with either miR-181a-2-3p inhibitor or inhibitor control. MGC-803/DDP and SGC-7901/DDP cells were then cultured with different DDP concentrations, following by viability assessment (Figure 5B). miR-181a-2-3p-knockdown in MGC-803/DDP and SGC-7901/DDP cells led to higher DDP IC_{50} values and increased survival rates, comparing to the inhibitor control cells (Figure 5C). Thus, miR-181a-2-3p-knockdown in MGC-803/DDP and SGC-7901/DDP cells displayed weaker DDP resistance, caused by increase in apoptosis and cytotoxicity. The above results substantiate that downregulation of miR-181a-2-3p sensitizes DDP sensitivity in gastric cancer cells.

Discussion

DDP resistance is an obstacle for effective therapy of GC. The identification of special biomarkers for DDP resistance will greatly contribute to the accurate diagnosis and effective treatment of gastric cancer. Role of miRNAs in DDP therapy remains unclear. miRNAs act a crucial role in the occurrence and development of tumors, which may be related to the drug resistance. For example, miR-21 downregulation in GC cells has been
reported to change survival rates via elevating DDP sensitivity.

Some reports have been published on the relationship between the miRNA utilization and the initiation, progression, diagnosis, appropriate treatment and prognosis of the GC. Fang et al reported that some cancer-related miRNAs (miR-338, miR-223, miR-21, and miR-10b) and tumor-inhibiting miRNAs (let-7a, miR-126, and miR-30a-5p) can serve as prognostic biomarkers in patients with gastric cancer. A large number of studies have reported the use of circulating miRNAs in combination to improve diagnostic accuracy, with an AUC greater than 0.8. Few reports have been reported on the application of miRNAs in the screening and diagnosis of DDP response in gastric cancer. In this study, sRNA-seq technology was utilized to establish the difference of miRNAs expression profiles between chemotherapy-resistant and chemotherapy-sensitive GC cells, and bioinformatics analysis was used to screen out the potential miRNAs. Our results displayed that miR-181a-2-3p was significantly upregulated in GC cells and patients resistant to chemotherapy. While some miRNAs are thought prognostic or diagnostic biomarkers for gastric cancer, our study is the first to explore their promising use in terms of DDP response. Besides, our observations indicated that higher levels of miR-181a-2-3p serum + tumor was a better biomarker than miR-181a-2-3p serum or miR-181a-2-3p tumor for chemoresistance in GC patients. miR-181a-2-3p serum + tumor could gain an AUC of 0.926. The equation was 0.591 × miR-181a-2-3p serum + 0.729 × miR-181a-2-3p tumor + 0.231. A large cohort analysis was performed via Kaplan–Meier survival data based on OncoLnc database, Kaplan–Meier Plotter database, OncomiR database, and Starbase database in order to find out the function of miR-181a-2-3p as a potential prognostic factor. The results suggested that miR-181a-2-3p overexpression could function as a valid biomarker for poor overall survival and chemoresistance.

Previous studies have shown that in cervical cancer, miR-181a-2-3p was crucial for the maintenance of cancer stem cells. In pancreatic ductal adenocarcinoma, miR-181a-2-3p could function as a biomarker for early detection. In this study, increased miR-181a-2-3p was found in DDP resistant GC cell lines and DDP resistant GC patients, and elevated levels of miR-181a-2-3p were correlated with poorer prognosis and worse clinical parameters. In addition, the interrelation between miR-181a-2-3p level and tumor size in this study is presented in Figure 5.
study indicated that miR-181a-2-3p may play an important role in the proliferation of tumor cells. This study revealed that miR-181a-2-3p upregulation increased cell proliferation, and inhibited apoptosis as well. Thus, a proven selective miR-181a-2-3p response modifier might be a viable and attractive treatment option. Some experiments should be performed to clarify the function of miR-181a-2-3p as treatment targets and clinical therapeutic potential.

Summarizing the shortcomings of the study, the sample size in bioinformatics analysis needs to be further expanded, and more animal study or human testing should be carried out in the future.

**Conclusion**

The present study reported on the potential for miR-181a-2-3p to predict the DDP therapeutic benefit in gastric cancer patients. Targeting oncogenic miR-181a-2-3p could inhibit growth and suppress cisplatin-mediated resistance of gastric cancer. Furthermore, DDP administration combined miR-181a-2-3p downregulation might be a promising therapeutic option for DDP-resistant GC patients in the future.

**Acknowledgments**

We thank the Scientific Research Start-up Fund of Beijing Friendship Hospital, Capital Medical University (yyqdkt2020-9 and yyqdkt2020-13) for financial support.

**Author Contributions**

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interests.

**References**


